ROCHE-H0649G

Study Sponsor: Roche

Study Title

A multinational open-label study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2lneu overexpression who have relapsed following one or two cytotoxic chemotherapy regimens for metastatic breast cancer.

Medicine or Vaccine (generic name)

trastuzumab

Sponsor Identification Number

H0649G

Trial Registry Identification Number(#'s)

Medical Condition

HER2-positive metastatic breast cancer

Phase

Phase 2

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Additional information about the data and documents available for this study

Date Added to this Site

July 2015